Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib Plus Lisocabtagene Maraleucel for Richter's Syndrome
NCT05873712Phase 2Recruiting
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Fragment-Derived Small Molecules, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, lisocabtagene maraleucel in Richter's syndrome (RS). Started Jul 2023; status: recruiting.
02
Drugs
zanubrutiniblisocabtagene maraleucel
03
Conditions
Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT05873712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873712.